Analyst from TD Cowen's questions to Beigene Ltd (ONC) leadership • Q4 2024
Question
An analyst from TD Cowen asked about the 2025 guidance expectations for TEVIMBRA in the U.S. and EU, and for details on the BTK degrader's combination strategy and its potential to move into earlier lines of therapy.
Answer
CEO John Oyler described the U.S. and EU launches of TEVIMBRA as being in 'early days' with a targeted investment approach. Global Head of R&D Lai Wang explained the BTK degrader's platform trial is exploring combinations for different indications, including CLL and other indolent lymphomas, and they are eagerly awaiting data to guide strategy.